Molecular aspects of pancreatic cancer and future perspectives

Digestive Surgery

Volumn 16, Issue 4, 1999, Pages 281-290

  Friess, Helmut ^a   Kleeff, Jörg ^a   Korc, Murray ^b   Büchler, Markus W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene mutations; Gene therapy; Growth factors; Pancreatic cancer

Indexed keywords

AMPHIREGULIN; CELL RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; LIGAND; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; CANCER INVASION; CANCER SURVIVAL; CELL DIFFERENTIATION; COMPETITIVE INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

GENE THERAPY; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032767855     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018737     Document Type: Review

References (142)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47: 5-27.
2. Gudjonsson B: Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-2303.
3. Friess H, Kleeff J, Silva JC, Sadowski C, Baer HU, Büchler MW: The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998;186:675-682.
4. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992;326: 455-465.
5. Beger HG, Büchler MW, Friess H: Surgical results and indications for adjuvant measures in pancreatic cancer. Chirurg 1994;65:246-252.
6. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. Jama 1985;253:2061-2067.
7. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Jr., Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluoruuracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48: 1705-1710.
8. Poen JC, Ford JM, Niederhuber JE: Chemoradiotherapy in the management of localized tumors of the pancreas. Ann Surg Oncol 1999;6: 117-122.
9. White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, Pappas T, Hurwitz H, Tyler D: Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999;6:38-45.
10. Takahashi S, Aiura K, Saitoh J, Hayatsu S, Kitajima M, Ogata Y: Treatment strategy for pancreatic head cancer: Pylorus-preserving pancreatoduodenectomy, intraoperative radiotherapy and portal catheterization. Digestion 1999;60(suppl 1):130-134.
11. Link KH, Leder G, Formentini A, Fortnagel G, Kornmann M, Schatz M, Beger HG: Surgery and multimodal treatments in pancreatic cancer: A review on the basis of future multimodal treatment concepts. Gan To Kagaku Ryoho 1999;26:10-40.
12. Andrén-Sandberg Å: Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report. Acta Chir Scand 1990;156:549-551.
13. Andrén-Sandberg Å, Johansson J: Influence of sex hormones on pancreatic cancer. Int J Pancreatol 1990;7:167-176.
14. Friess H, Büchler M, Kiesel L, Kruger M, Beger HG: LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatol 1991; 10:151-159.
15. Friess H, Büchler M, Kruger M, Beger HG: Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 1992;7:516-521.
16. Friess H, Büchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540-545.
17. Büchler M, Friess H, Schultheiss KH, Gebhardt C, Kubel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, et al: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/ 32) in resectable pancreatic cancer. Cancer 1991;68:1507-1512.
18. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M: Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-191.
19. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Büchler M, Beger HG, Korc M: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-160.
20. Kondoh S, Kaino M, Okita S, Ryozawa S, Akiyama T, Okita K: Detection of Ki-ras and p53 gene mutations in tissue and pancreatic juice from pancreatic adenocarcinomas. J Gastroenterol 1998;33:390-396.
21. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, Yaegashi S, Konishi Y, Sekiya T: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-181.
22. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54: 1556-1560.
23. Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK: Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 1996;12:10-17.
24. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-1543.
25. Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
26. Sarkar FH, Ball DE, Li YW, Crissman JD: Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene. DNA Cell Biol 1993;12:611-615.
27. Prigent SA, Lemoine NR: The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992;4: 1-24.
28. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86: 9193-9197.
29. Carraway KL 3rd, Cantley LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
30. Laurence DJ, Gusterson BA: The epidermal growth factor. A review of structural and functional relationships in the normal organism and in cancer cells. Tumour Biol 1990;11:229-261.
31. Sierke SL, Cheng K, Kim HH, Koland JG: Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 1997;322: 757-763.
32. Fiddes RJ, Janes PW, Sivertsen SP, Sutherland RL, Musgrove EA, Daly RJ: Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T- 47D human breast cancer cells. Oncogene 1998;16:2803-2813.
33. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ: ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997;15:2705-2716.
34. Riese DJ, 2nd. Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
35. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH: Cooperative signaling of ErbB3 and ErhB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10:1813-1821.
36. Gamett DC, Pearson G, Cerione RA, Friedberg I: Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 1997;272:12052-12056.
37. van der Heyden MA, Van Bergen en Henegouwen PM, de Ruiter N, Verdaasdonk MA, van den Tweel JG, Rijksen G, Boonstra J, Joling P: The actin binding domain of the epidermal growth factor receptor is required for EGF-stimulated tissue invasion. Exp Cell Res 1997; 234:521-526.
38. Yamada M, Ikeuchi T, Hatanaka H: The neurotrophic action and signalling of epidermal growth factor. Prog Neurobiol 1997;51:19-37.
39. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995;20:117-122.
40. Errede B, Cade RM, Yashar BM, Kamada Y, Levin DE, Irie K, Matsumoto K: Dynamics and organization of MAP kinase signal pathways. Mol Reprod Dev 1995;42:477-485.
41. Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL: MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c- Jun amino-terminal kinases? Curr Opin Genet Dev 1997;7:67-74.
42. Schlesinger TK, Fanger GR, Yujiri T, Johnson GL: The TAO of MEKK. Front Biosci 1998; 3:D1181-D1186.
43. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995;9:726-735.
44. Friess H, Yamanaka Y, Kobrin MS, Do DA, Büchler MW, Korc M: Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1:1413-1420.
45. Korc M, Chandrasckar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-1360.
46. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG, Korc M: Overexpression of HER2/neu oncogene in human pancreatic carcinoma [see comments]. Hum Pathol 1993;24:1127-1134.
47. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ: The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166:7-12.
48. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G: The erbB-3 gene in human pancreatic cancer. J Pathol 1992;168:269-273.
49. Graber HU, Friess H, Kaufmann B, Willi D, Zimmermann A, Korc M, Büchler MW: ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer 1999;84: 24-27.
50. Carraway KL, 3rd. Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C: Neuregulin-2, a new ligand of ErbB3/ErbB4-rcceptor tyrosine kinases. Nature 1997;387:512-516
51. Chang H, Riese DJ 2nd, Gilbert W, Stern DF, McMahan UJ: Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 1997;387:509-512.
52. Davis-Fleischer KM, Besner GE: Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Front Biosci 1998:3:d288-d299.
53. Derynck R: The physiology of transforming growth factor-alpha. Adv Cancer Res 1992;58:27-52.
54. Kudlow JE, Bjorge JD: TGF alpha in normal physiology. Semin Cancer Biol 1990:1:293-302.
55. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteehe CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990;10: 1969-1981.
56. Sasada R, Ono Y, Taniyama Y, Shing Y, Folkman J, Igarashi K: Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family. Biochem Biophys Res Commun 1993;190:1173-1179.
57. Toyoda H, Komurasaki T, Uchida D, Morimoto S: Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997;326:69-75.
58. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ: Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 1997;94:9567-9567.
59. Di Marco E, Pierce JH, Aaronson SA, Di Fiore PP: Mechanisms by which EGF receptor and TGF alpha contribute to malignant transformation. Nat Immun Cell Growth Regul 1990; 9:209-221.
60. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Büchler MW, Johnson GR, Korc M: Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994; 54:3959-3962.
61. Kobrin MS, Funatomi H, Friess H, Büchler MW, Stathis P, Korc M: Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202:1705-1709.
62. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Beger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-569.
63. Lemoine NR, Hall PA: Growth factors and oncogenes in pancreatic cancer. Baillières Clin Gastroenterol 1990;4:815-832.
64. Wagner M, Luhrs H, Kloppel G, Adler G, Schmid RM: Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 1998;115:1254-1262.
65. Wagner M, Cao T, Lopez ME, Hope C, van Nostrand K, Kobrin MS, Fan HU, Büchler MW, Korc M: Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Im J Cancer 1996;68: 782-787.
66. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
67. Derynck R, Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1997;1333: F105-F150.
68. Heldin CH, Miyazono K, ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-471.
69. Bloom BB, Humphries DE, Kuang PP, Fine A, Goldstein RH: Structure and expression of the promoter for the R4/AEK5 human type I transforming growth factor-beta receptor: Regulation by TGF-beta. Biochim Biophys Acta 1996; 1312:243-248.
70. Derynck R, Zhang Y, Feng XH: Smads: Transcriptional activators of TGF-beta responses. Cell 1998;95:737-740.
71. Kretzschmar M, Massague J: SMADs: Mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998;8:103-111.
72. Liu F, Pouponnot C, Massague J: Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 1997;11:3157-3167.
73. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa ET, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-353.
74. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A: Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998;12:186-197.
75. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K: Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997;389:622-626.
76. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-635.
77. Kretzschmar M, Liu F, Hata A, Doody J, Massague J: The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 1997;11:984-995.
78. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JE: Specific activation of Smadl signaling pathways by the BMP7 type I receptor. ALK.2. J Biol Chem 1998;273:25628-25636.
79. Yamamoto N, Akiyama S, Katagiri T, Namiki M, Kurokawa T, Suda T: Smad1 and smad5 act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts. Biochem Biophys Res Commun 1997;238:574-580.
80. Hata A, Shi Y, Massague J: TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 1998;4:257-262.
81. Theodorescu D, Bergsma D, Man MS, Elshourbagy N, Sheehan C, Rieman D, Kerbel RS: Cloning and overexpression of TGF-bcta 1 cDNA in a mammary adenocarcinoma: In vitro and in vivo effects. Growth Factors 1991;5: 305-316.
82. Naef M, Ishiwata T, Friess H, Büchler MW, Gold LI, Korc M: Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer 1997;71:131-137.
83. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105: 1846-1856.
84. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Büchler MW, Korc M: Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition. Int J Cancer 1996;67: 283-288.
85. Kleeff J, Korc M: Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-b1ta 1 in COLO-357 cells. J Biol Chem 1998;273:7495-7500.
86. Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL, Zhang W, Chiao PJ: Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-3934.
87. Friess H, Yamanaka Y, Büchler M, Berger HG, Kobrin MS, Baldwin RL, Korc M: Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-2707.
88. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, Korc M, Büchler MW: Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42: 2054-2063.
89. Wagner M, Kleeff J, Lopez ME, Bockman I, Massaque J, Korc M: Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 1998;78:255-260.
90. Le Dai J, Turnacioglu KK, Schutte M, Sugar AY, Kern SE: Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 1998;58:4592-4597.
91. Lagna G. Hata A, Hemmati-Brivanlou A, Massague J: Partnership between DPC4 and SMAD proteins in TGF-heta signalling path-ways. Nature 1996;383:832-836.
92. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA, Jr. Meltzer PS, Hahn SA, Kern SE: DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
93. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58:5329-5332.
94. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, de Villalonga P, Agell N, Lluis F, Bachs O, Capella G: Disruption of the antiproliferative TGF- beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-1978.
95. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, et al: A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547.
96. Iacopetta BJ, Welch J, Soong R, House AK, Zhou XP, Hamelin R: Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: Relationship to clinicopathological features and genetic alterations. J Pathol 1998;184:390-395.
97. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, Markowitz S: Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-3104.
98. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, Korc M: Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999;255:268-273.
99. Kleeff J, Ishiwata T, Maruyama H, Friess H, Troung P, Büchler MW, Falb D, Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999, in press.
100. Brunner N, Pyke C, Hansen CH, Romer J, Grondahl-Hansen J, Dane K: Urokinasc plasminogen activator (uP.A) and its type 1 inhibitor (PAI-1): Regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 1994;71: 299-309.
101. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998;13:893-906.
102. Kleef J, Ishiwata T, Friess H, Büchler MW, Korc M: Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860-868.
103. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler M, Korc M: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116:1202-1216.
104. Kerkhoff E, Rapp UR: Cell cycle targets of Ras/Raf signalling. Oncogene 1998;17:1457-1462.
105. Sternberg PW, Alberola-Ila J: Conspiracy theory: RAS and RAF do not act alone. Cell 1998;95:447-450.
106. Longnecker DS, Terhune PG: What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas 1998;17:323-324.
107. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G: Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-236.
108. Capella G, Cronauer-Mitra S, Pienado MA, Perucho M: Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991;93:125-131.
109. Lane DP, Benchimol S: p53: Oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
110. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991;351: 453-456.
111. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, et al.: Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-1082.
112. Kasuya K, Watanabe H, Nakasako T, Ajioka Y. Koyanagi Y: p53 protein overexpression and K-ras codon 12 mutation in pancreatic ductal carcinoma: Correlation with histologic factors. Pathol Int 1997;47:531-539.
113. Harada N, Gansauge S, Gansauge F, Cause H, Shimoyama S, Imaizumi T, Mattfeld T, Schoenberg MH, Beger HG: Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer 1997;76:299-305.
114. Schwartz D, Rotter V: p53-dependent cell cycle control: Response to genotoxic stress. Semin Cancer Biol 1998;8:325-336.
115. Kastan MB, Canman CE, Leonard CJ: P53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 1995;14: 3-15.
116. Shaw PH: The role of p53 in cell cycle regulation. Pathol Res Pract 1996;192:669-675.
117. Wiman KG: p53: Emergency brake and target for cancer therapy. Exp Cell Res 1997;237: 14-18.
118. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Büchler MW: Bax, but not bd-2. influences the prognosis of human pancreatic cancer. Gut 1998;43:414-421.
119. Friess H, Lu Z, Andren-Sandberg A, Berberat P. Zimmermann A, Adler G, Schmid R, Büchler MW: Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998; 228:780-787.
120. Gansauge S, Gansauge F, Yang Y, Muller J, Seufferlein T, Ramadani M, Beger HG: Interleukin 1 beta-converting enzyme (caspase-1) is overexpresscd in adenocarcinomaof the pancreas. Cancer Res 1998;58:2703-2706.
121. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58:1741-1749.
122. Raitano AB, Korc M: Tumor necrosis factor up-regulates gamma-interferon binding in a human carcinoma cell line. J Biol Chem 1990;265:10466-10472.
123. Raitano AB, Scuderi P, Korc M: Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 1990;5:267-277.
124. Raitano AB, Scuderi P, Korc M: Long-term effect of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Int J Pancreatol 1990;6:109-118.
125. Kleeff J, Ishiwata T, Friess H, Büchler MW, Israel MA, Korc M: The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res 1998;58:3769-3772.
126. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Büchler MW: KAI 1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996;56:4876-4880.
127. Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, Büchler MW: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer 1998;79:349-355.
128. Evoy D, Hirschowitz EA, Naama HA, Li XK, Crystal RG, Daly JM, Lieberman MD: In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997;69:226-231.
129. Green N, Youngs D, Neoptolemos J: Sensitization of colorectal and pancreatic cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997;4:229-238.
130. Rosenfeld M, Vickers S, Raben D: Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997;225: 609-620.
131. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D: Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224:405-417.
132. Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, Terada M: Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997;8:1105-1113
133. Block A, Chen SH, Kosai K, Finegold M, Woo SL: Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 1997;15:25-34.
134. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Person DZ, Hong WR, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
135. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA: Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5:681-688.
136. Hwang RF, Gordon EM, Anderson WF, Parekh D: Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998;124:143-150.
137. Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH: Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 1998;16:107-113.
138. Caldas C, Hahn SA, Dacosta LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
139. Simeone D, Cascarelli A, Logsdon C: Adenoviral-mediated gene transfer of a constitutively active retinoblastoma gene inhibits human pancreatic tumor cell proliferation. Surgery 1997;122:428-434.
140. Pearson AS, Bouvet M, Evans DB, Roth JA: Gene therapy and pancreatic cancer. Front Biosci 1998;3:230-237.
141. Aoki K, Yoshida T, Sugimura T, Terada M: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-3816.
142. Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N: Suppression of pancreatic cancer by the dominant negative ras mutant. J Surg Res 1996;142:63-71.